London Healthcare Week: As the company gears up for its first phase 3 trials, MindMed's CEO says he sees a tailwind of regulatory support for the psychedelics space

blonca9
Nov 21, 2024
1 min read

Updated: Nov 27, 2024

Robert Barrow discusses MindMed's LSD based program that is going into phase 3 studies for generalized anxiety disorder and major depressive disorder and an earlier stage R(-)-MDMA program for autism spectrum disorder.

Recent Posts

See All

Checking in with the co-founders of Amylyx Pharmaceuticals, which now has one program in pivotal, another that may start soon, and earlier stage clinical programs that will have data this year

Oxford, UK based Pathios Therapeutics is targeting GPR65 for cancer, a signaling pathway that becomes active in the low pH tumor microenvironment and causes immunosuppression and high angiogenesis

AI News: Emeryville based Fauna Bio launched Fauna Brain, an AI platform that uses both internal and external data sets, and an analysis of the literature, to allow users to identify and score targets

London Healthcare Week: As the company gears up for its first phase 3 trials, MindMed's CEO says he sees a tailwind of regulatory support for the psychedelics space

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight